Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy.
Louis R, Harrison TW, Chanez P, Menzella F, Philteos G, Cosio BG, Lugogo NL, de Luiz G, Burden A, Adlington T, Keeling N, Kwiatek J, Garcia Gil E; ANDHI Study Investigators. Louis R, et al. Among authors: menzella f. J Allergy Clin Immunol Pract. 2023 Jun;11(6):1759-1770.e7. doi: 10.1016/j.jaip.2023.03.009. Epub 2023 Mar 21. J Allergy Clin Immunol Pract. 2023. PMID: 36948488 Free article.
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG; ANDHI study investigators. Harrison TW, et al. Among authors: menzella f. Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22. Lancet Respir Med. 2021. PMID: 33357499 Clinical Trial.
Tezepelumab: patient selection and place in therapy in severe asthma.
Menzella F, Munari S, Corsi L, Tonin S, Cestaro W, Ballarin A, Floriani A, Dartora C, Senna G. Menzella F, et al. J Int Med Res. 2024 Apr;52(4):3000605241246740. doi: 10.1177/03000605241246740. J Int Med Res. 2024. PMID: 38676539 Free PMC article. Review.
Asthma management, focused on the use of oral corticosteroids: the opinions of Italian asthmatic patients.
Latorre M, Rizzi A, Paggiaro P, Baiardini I, Bagnasco D, DelGiacco S, Lombardi C, Patella V, Nucera E, Parente R, Paoletti G, Pini L, Ridolo E, Senna G, Blasi F, Canonica GW, Aruanno A, Ballacchino C, Bonavia M, Calabrese C, Caminati M, Carbonara M, Cardini C, Caruso C, Cattani L, Crivellaro MA, Diana A, Durante E, Favero E, Barbaro MPF, Frateiacci S, Guarnieri G, Lofaro A, Losa F, Magarò N, Menzella F, Ricciardi L, Scioscia G, Testino E, Torracca F. Latorre M, et al. Among authors: menzella f. J Asthma. 2024 Apr 5:1-26. doi: 10.1080/02770903.2024.2338863. Online ahead of print. J Asthma. 2024. PMID: 38578082
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study.
Cameli P, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa MF, Canonica GW, Caruso C, Centanni S, D'Amato M, De Michele F, Del Giacco S, Di Marco F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Senna G, Vultaggio A, Benci M, Boarino S, Menzella F. Cameli P, et al. Among authors: menzella f. J Asthma Allergy. 2024 Mar 27;17:273-290. doi: 10.2147/JAA.S438981. eCollection 2024. J Asthma Allergy. 2024. PMID: 38562251 Free PMC article.
Chronic rhinosinusitis with nasal polyposis and biological agents: the ARIA-ITALY Survey.
Lombardi C, Passalacqua G, Menzella F, Mauritz Canevari RF, Danesi G, Pusateri AM, Carone M, Vancheri C, Di Marco F, Micheletto C, Manzotti G, Di Gioacchino M, Bilò MB, Gelardi M, Senna G, Canonica GW; ARIA Italy Panel. Lombardi C, et al. Among authors: menzella f. Eur Ann Allergy Clin Immunol. 2024 Mar 27. doi: 10.23822/EurAnnACI.1764-1489.338. Online ahead of print. Eur Ann Allergy Clin Immunol. 2024. PMID: 38534135 Free article.
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Mannent LP, Patel N, Staudinger HW, Yancopoulos GD, Mortensen ER, Akinlade B, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM; BOREAS Investigators. Bhatt SP, et al. N Engl J Med. 2023 Jul 20;389(3):205-214. doi: 10.1056/NEJMoa2303951. Epub 2023 May 21. N Engl J Med. 2023. PMID: 37272521 Clinical Trial.
110 results